Clinical trials: ACS
Acute Coronary Syndrome, Continuous Glucose Measurement
Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS
Disorders of glycemic regulation are common in patients hospitalized for acute coronary syndrome (ACS). Abnormal glycaemia is observed in 50% of cases, in 30-40% diabetes, and in 25-35% fasting hyperglycaemia or glucose…
- Conditions
- Acute Coronary Syndrome, Continuous Glucose Measurement, Glycemic Variability, Cardiovascular Event
- Trial name
- FREESCA (NCT06014112)
- Testing
- Freestyle Libre Pro iQ
- Where
- 9 sites in France
- Volunteers
- 850 people
- Sponsor
- University Hospital, Montpellier
Acute Coronary Syndrome, Coronary Artery Disease
Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study
Subjects presenting with probable acute coronary syndromes scheduled for cardiac catheterization will be enrolled in this study.
- Trial name
- NCT01916902
- Testing
- Ticagrelor- Delayed Administration, Ticagrelor- Immediate Administration, Optical Coherence Tomography
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Acute Coronary Syndrome
Identification of Clopidogrel CYP2C19 Metabolizer and Thienopyridine Treatment After an Acute Coronary Syndrome
To demonstrate that a strategy of fast genetic testing performed in outpatient clinic allows to select adequately one of the 2 antiplatelet treatments approved in the same indication (ACS with PCI - prasugrel 10mg MD or…
- Trial name
- GAMMA (NCT01390974)
- Where
- France
- Volunteers
- 270 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-ST or ST Elevation Acute Coronary Syndromes
A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS
The purpose of this study is to test the hypothesis that the onset of the antiplatelet effect of ticagrelor is more rapid and greater than clopidogrel in Chinese patients with ACS.
- Trial name
- HouYi (NCT01864005)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, NSTEMI - Non-ST Segment Elevation MI
Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg
Acute Coronary Syndrome (ACS) is triggered by the rupture of an atherosclerotic plaque that results in a platelet aggregation reaction in the coronary artery.
- Conditions
- Diabetes Mellitus, Type 2, NSTEMI - Non-ST Segment Elevation MI, Coronary Angioplasty
- Trial name
- IDASCOP 1 (NCT03329261)
- Testing
- Clopidogrel
- Where
- Tunisia
- Volunteers
- 167 people
- Sponsor
- Laboratoires Teriak
Acute Coronary Syndrome, Air Pollution
Air Pollution Exposure on Acute Coronary Syndrome in Two Cohorts of Industrial and Non-industrial Areas
Background: There is a lack of data on the effect of air pollution on acute coronary syndrome (ACS) in industrial and non-industrial areas.
- Trial name
- NCT04539925
- Testing
- Acute coronary syndrome
- Where
- 2 sites in Poland
- Volunteers
- 9,046 people
- Sponsor
- Medical University of Silesia
ACS - Acute Coronary Syndrome, Oncology
The BRAvAdO Registry
The BRAVADO Registry pretends to identify stratification, diagnosis, total atherosclerotic burden and treatment approaches in oncologic patients with Acute Coronary Syndrome (ACS) and identify strategies to improve health care…
- Trial name
- BRAvAdO (NCT04222608)
- Where
- Brazil
- Volunteers
- 600 people
- Sponsor
- University of Sao Paulo General Hospital
Knee Arthritis Osteoarthritis, Platelet Rich Plasma Injection
Comparison of Platelet-rich Plasma and Activated Cytokine-rich Serum Injection Treatments in Patients With Knee Osteoarthritis. (KOA PRP ACS)
The effects of single dose injection of platelet rich plasma or conditioned serum in the knee joint in patients with knee osteoarthritis will be compared
- Conditions
- Knee Arthritis Osteoarthritis, Platelet Rich Plasma Injection, Conditioned Serum
- Trial name
- KOA PRP ACS (NCT07473232)
- Testing
- Autologous Platelet-Rich Plasma (PRP), Conditioned serum (CS)
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Pamukkale University
Acute Coronary Syndrome
Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of ACS
Antiplatelet agents are cornerstones for management of ischemic heart disease. For patients suffering from acute coronary syndrome (heart attack), treatment with aspirin and ticagrelor are typically given for one year after index…
- Trial name
- FMD_ACS (NCT03881943)
- Testing
- Ticagrelor 60 mg, Aspirin 100 MG Oral Tablet, Enteric Coated
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The University of Hong Kong
Safety Issues, Effect of Drug
Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation ACS Patients
The aim of this study is evaluating safety and effectiveness of Ovine Enoxaparin Sodium in Non-ST-Segment Elevation Acute Coronary Syndrome (NSTEACS) Patients
- Trial name
- NCT06114641
- Testing
- Enoxaparin sodium injection
- Where
- 3 sites in Indonesia
- Volunteers
- 220 people
- Sponsor
- PT Bio Farma
Coronary Artery Disease, Myocardial Ischemia
Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
A real world registry to compare dual therapy with Dabigatran/Ticagrelor to dual therapie with Dabigatran/Clopidogrel in patients with an indication for NOAC undergoing PCI in the setting of ACS.
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction, Atrial Fibrillation
- Trial name
- RE-DUAL PCI (NCT04688723)
- Testing
- Dabigatran + Ticagrelor, Dabigatran + clopidogrel
- Where
- Netherlands
- Volunteers
- 1,000 people
- Sponsor
- Zuyderland Medisch Centrum
Coronary Arterial Disease (CAD), Vulnerable Coronary Plaques
Ticin Pilot Study: Sirolimus-Eluting Balloon for Stabilization and Regression of Non-Obstructive Coronary Plaques.
The goal of this pilot clinical trial is to evaluate the use of the Selution SLR sirolimus-eluting balloon, in addition to guideline-directed medical therapy (GDMT), for the preventive treatment of non-flow-limiting vulnerable…
- Conditions
- Coronary Arterial Disease (CAD), Vulnerable Coronary Plaques, Multivessel Coronary Artery Disease, Coronary Vessel
- Trial name
- NCT06928883
- Testing
- Sirolimus drug eluting ballooon therapy, Optimal guidelines-directed medical therapies (GDMT)
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- Cardiocentro Ticino
Type 2 Diabetes Mellitus, Coronary Heart Disease
Glycemic Variability, Gut Microbiota, and Prognosis in T2DM With ACS
Patients with type 2 diabetes mellitus (T2DM) diagnosed with acute coronary syndrome (ACS) by coronary angiography in the Second Affiliated Hospital of Nanchang University were consecutively included in a prospective cohort…
- Trial name
- NCT06573060
- Testing
- Continuous glucose monitoring
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), Anxiety
Educational Video to Improve Understanding and Reduce Anxiety in Heart Attack Patients
Patients who are diagnosed with a heart attack are often confronted with an unexpected hospital admission and an urgent heart catheterization.
- Conditions
- Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), Anxiety, Patient Education Materials
- Trial name
- VID-ACS (NCT07424482)
- Testing
- Educational Video
- Where
- Germany
- Volunteers
- 140 people
- Sponsor
- Tobias Schreiber
Acute Coronary Syndrome
MT1002 Phase II Study in ACS Patients With PCI
This is an open-label, sequential-dose escalation/de-escalation trial testing 3 dose levels of MT1002 in patients undergoing PCI due to ACS with NSTEMI.
- Trial name
- NCT04723186
- Testing
- MT1002 for Injection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Acute Coronary Syndrome
Myocardial Infarction Registry
The single-center MIR-registry was created to assess real-world prevalence, demographic characteristics and management of patients with acute coronary syndrome presenting in the emergency department (ED) of University of…
- Trial name
- MIR (NCT06128317)
- Testing
- no intervention is intended.
- Where
- Germany
- Volunteers
- 2,500 people
- Sponsor
- University Hospital Heidelberg
Acute Coronary Syndrome (ACS), Myocardial Infarction
VITROS Immunodiagnostic Products hs Troponin I
The purpose of this clinical study is to collect data to substantiate the use of the VITROS hs Troponin I test as an aid in the diagnosis of myocardial infarction (MI).
- Trial name
- NCT03581578
- Where
- 24 sites in United States
- Volunteers
- 1,630 people
- Sponsor
- Ortho-Clinical Diagnostics, Inc.
Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication
Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO
The SURVIVE trial aims to test whether using an anti-thrombotic regimen involving cangrelor can reduce bleeding risk while maintaining effective antithrombotic effects in patients on VA-ECMO due to cardiogenic shock (CS)/ cardiac…
- Conditions
- Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication, Platelet Dysfunction
- Trial name
- SURVIVE (NCT06792643)
- Testing
- Cangrelor
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
ACS - Acute Coronary Syndrome
Positive Emotions After Acute Coronary Events at Northwestern University
This study is a single-arm, 12-week trial to test the feasibility of a PP-MI intervention for patients recently admitted following ACS.
- Trial name
- PEACE-NU (NCT04062383)
- Testing
- Positive Psychology + Motivational Interviewing
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
Heart Attack, Stroke
ACS Registry - A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow
Cardiovascular diseases (CVD) are currently the leading cause of death in industrialized countries and are expected to become the leading cause of death in emerging countries by 20201.
- Conditions
- Heart Attack, Stroke, Cardiovascular Death
- Trial name
- NCT03654157
- Where
- 27 sites in Russia
- Volunteers
- 1,576 people
- Sponsor
- AstraZeneca